David Bader, MD
Cardiovascular Disease · Wakefield, RINPI 1710913868
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $200 of the $300 with a category attached, or 66.7%. 6 manufacturers reported payments, led by United Therapeutics Corporation at 33.3% of the total. That places this record below the midpoint for cardiovascular disease clinicians in RI, where the typical reported total is $360.
Across 6 payments — averaging $50.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$100
- Boston Scientific$81
- Edwards Lifesciences$36
- Lantheus Medical Imaging, Inc.$31
- Davol Inc.$29
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$23
What the payments were for
- Speaking & faculty fees$10033%
- Food & beverage$20067%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 1 | $100 |
| Boston Scientific | 1 | $81 |
| Edwards Lifesciences | 1 | $36 |
| Lantheus Medical Imaging, Inc. | 1 | $31 |
| Davol Inc. | 1 | $29 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $23 |
How this compares
$300 in reported general payments places this provider in the 45th percentile of 86 cardiovascular disease providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,102 | $898,568 |
| XareltoRivaroxaban | 203 | $198,600 |
| JardianceEmpagliflozin | 125 | $114,738 |
| EntrestoSacubitril/Valsartan | 151 | $111,299 |
| Repatha SureclickEvolocumab | 53 | $56,070 |
| Dofetilide | 71 | $12,059 |
| BrilintaTicagrelor | 24 | $10,803 |
| Praluent PenAlirocumab | 19 | $9,799 |
| Metoprolol Succinate | 575 | $8,884 |
| Atorvastatin Calcium | 680 | $7,994 |
| Repatha PushtronexEvolocumab | 11 | $6,282 |
| Rosuvastatin Calcium | 289 | $4,988 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 119 | $4,224 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 15 | $4,207 |
| Ezetimibe | 221 | $3,569 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Wakefield
- Aaron WeisbordWakefield$4K
- Steven FeraWakefield$808
- Neil BrandonWakefield$232
- Ibrahim ElgabryWoonsocket$72K
- Ara SadaniantzProvidence$27K
- George BourganosWoonsocket$16K
- Edward ThomasWarwick$15K
- John CavaProvidence$12K
- Jeremy LumProvidence$10K
- Franklin SchneiderProvidence$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.